252 related articles for article (PubMed ID: 37934376)
21. Cost-Effectiveness of Adding Androgen Deprivation Therapy to Radiation Therapy for Men with Advanced Prostate Cancer from a U.S. Payer's Perspective.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Manag Care Spec Pharm; 2019 Feb; 25(2):225-234. PubMed ID: 30698095
[TBL] [Abstract][Full Text] [Related]
22. Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis.
Burian E; Palla B; Callahan N; Pyka T; Wolff C; von Schacky CE; Schmid A; Froelich MF; Rübenthaler J; Makowski MR; Gassert FG
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3870-3877. PubMed ID: 35606526
[TBL] [Abstract][Full Text] [Related]
23. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
[TBL] [Abstract][Full Text] [Related]
24.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
25. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
26. Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it.
Rowe SP; Voter AF; Werner RA; Zukotynski KA; Pomper MG; Gorin MA; Solnes LB
Can J Urol; 2023 Feb; 30(1):11432-11437. PubMed ID: 36779950
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
28. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
29. Piflufolastat F 18: Diagnostic First Approval.
Keam SJ
Mol Diagn Ther; 2021 Sep; 25(5):647-656. PubMed ID: 34292532
[TBL] [Abstract][Full Text] [Related]
30. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.
Chow KM; So WZ; Lee HJ; Lee A; Yap DWT; Takwoingi Y; Tay KJ; Tuan J; Thang SP; Lam W; Yuen J; Lawrentschuk N; Hofman MS; Murphy DG; Chen K
Eur Urol; 2023 Jul; 84(1):36-48. PubMed ID: 37032189
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
33. Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review.
Valle L; Shabsovich D; de Meerleer G; Maurer T; Murphy DG; Nickols NG; Vapiwala N; Calais J; Kishan AU
Eur Urol Oncol; 2021 Jun; 4(3):339-355. PubMed ID: 33637464
[TBL] [Abstract][Full Text] [Related]
34. Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences.
Hwang L; Paluch J; Jadvar H; England JR; Desai B; Ballas LK
Clin Nucl Med; 2020 Sep; 45(9):668-671. PubMed ID: 32520496
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
[TBL] [Abstract][Full Text] [Related]
36. Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis.
Wei Y; Hay JW; Hay AR; Suen SC
BMC Urol; 2022 May; 22(1):76. PubMed ID: 35550071
[TBL] [Abstract][Full Text] [Related]
37. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
38. Evaluating appropriateness of 18F-fluciclovine PET/CT relative to standard of care imaging guidelines and the impact of ADT on positivity: a prospective study in 62 Veterans Administration patients at a single institution.
Green A; Temsah P; Goldfarb L; Sanfolippo K; Knoche E; Muzaffar R; Osman MM
Nucl Med Commun; 2024 Jun; 45(6):526-535. PubMed ID: 38517329
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.
Chiang CL; So TH; Lam TC; Choi HCW
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):108-115. PubMed ID: 31273290
[TBL] [Abstract][Full Text] [Related]
40. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
